Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors
about
Closing the door to human immunodeficiency virus.HIV-1 and influenza antibodies: seeing antigens in new waysResistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors.Peptides corresponding to the predicted heptad repeat 2 domain of the feline coronavirus spike protein are potent inhibitors of viral infectionBiochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor designInteractions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.Pharmacotherapy of pediatric and adolescent HIV infectionRecent advances in antiretroviral drugs.Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocketPeptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014).Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket.Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.Drug-resistant viruses may repair impaired fitness by mutations outside the drug target site.Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.Effect of amphipathic HIV fusion inhibitor peptides on POPC and POPC/cholesterol membrane properties: a molecular simulation study.HIV vs. HIV: Turning HIV-Derived Peptides into Drugs
P2860
Q30428089-C11A746C-078A-4DFB-99BD-C2E79201C87EQ33552488-262CD95C-8164-494F-834B-61DAD06EC82CQ34385987-FD942A8A-CC22-48B6-AE19-9341C7C6ABA1Q35061450-BE058B72-73C7-4BD2-9621-2885C02C67D0Q35563298-4A159F4A-A030-42EC-AB0B-E4E4E7937651Q35787743-B47947CC-DE00-4137-8D59-443E8ECF1EEAQ37240305-9F3886BC-8E6E-41D4-B1EE-7FA8701EBA5DQ37779092-7875B6FC-C38E-4C62-BA7F-829DC8C23C13Q38076321-344B401E-467F-4DE9-85AC-687DABFB542AQ38271873-E0BA58A8-0854-4672-91B3-2A58FAA80E09Q39455561-6BE7AFEB-1100-408E-928F-A003713ECE42Q39843204-697045EF-568E-43F5-BCA9-75545612851FQ39974054-EE0D322A-C23B-4603-9E1C-8A3F6E02C729Q40141950-082EDEB2-127C-4571-8529-81A5DB2D625BQ41770502-5D0C3594-87B2-4127-95B5-2488C7D45208Q58626543-10735D31-3B4A-4A51-8D52-FD8349B8EA76
P2860
Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Synergistic efficacy of combin ...... neration HIV-fusion inhibitors
@en
Synergistic efficacy of combin ...... eration HIV-fusion inhibitors.
@nl
type
label
Synergistic efficacy of combin ...... neration HIV-fusion inhibitors
@en
Synergistic efficacy of combin ...... eration HIV-fusion inhibitors.
@nl
prefLabel
Synergistic efficacy of combin ...... neration HIV-fusion inhibitors
@en
Synergistic efficacy of combin ...... eration HIV-fusion inhibitors.
@nl
P2093
P2860
P1433
P1476
Synergistic efficacy of combin ...... neration HIV-fusion inhibitors
@en
P2093
P2860
P304
P356
10.1097/QAD.0B013E328325A4CD
P407
P50
P577
2009-03-01T00:00:00Z